New Publication Highlights Transient Increases in Creatinine or Tubular Injury Markers in Heart Failure Patients Should Not Dissuade Use of Ultrafiltration
The study, titled, “Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function” further analyzed data on renal tubular injury biomarkers from a subset of 105 participants in the CARRESS-HF trial. The study supports that increases in serum creatinine should not be the major factor to dissuade decongestion by ultrafiltration or diuretics in patients where a therapeutic advantage may exist. Even if creatinine worsened and tubular biomarkers increased, renal function usually recovered by 60 days. In fact, participants with an increase in urinary biomarkers (who had 12-fold-increase odds of worsening renal function defined by a 20% change in serum creatinine) had the greatest improvement in kidney function at 60 days. Thus, changes in serum creatinine or kidney injury biomarkers should be discouraged as a surrogate endpoint in heart failure trials. Study authors concluded that modest or transient increases in creatinine levels, or increases in renal tubule injury biomarkers were outweighed by the benefits of decongestion, which aligns with the review conducted by Drs. Costanzo and Kazory published in the
“In the past, we have received some criticism regarding the increase in creatinine levels with ultrafiltration, such as with the Aquadex FlexFlow® system, and our response has been that the ultimate benefits outweighed potential risks. This analysis is yet another study that supports this assertion, with the added information that increases in serum creatinine levels were associated with superior decongestion and recovery of renal function at 60-days even in the presence of renal tubule injury biomarkers,” commented
About
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the clinical performance of the Aquadex FlexFlow system. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
1https://www.ncbi.nlm.nih.gov/pubmed/31163974
2https://www.ncbi.nlm.nih.gov/pubmed/29671929
CONTACTS: INVESTORS:Claudia Napal Drayton Chief Financial OfficerCHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com -or-Bret Shapiro Managing Partner CORE IR 516-222-2560 brets@coreir.comwww.coreir.com MEDIAJules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com
Source: CHF Solutions, Inc.